CG Oncology (CGON) Depreciation & Amortization (CF) (2023 - 2026)
CG Oncology's (CGON) quarterly Depreciation & Amortization (CF) came in at $841000.0 in Q1 2026, up 3404.17% YoY from $24000.0 in Q1 2025, and down 0.94% on a QoQ basis from $849000.0 in Q4 2025.
CG Oncology (CGON) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $841000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 3404.17% year-over-year to $841000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 4250.0% YoY) and the FY2025 annual result came in at $1.4 million, up 4415.62% from the prior year.
- Depreciation & Amortization (CF) fell to $841000.0 in Q1 2026, from $849000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $849000.0 in Q4 2025 to a low of $4000.0 in Q1 2023.
- A 4-year average of $194583.3 and a median of $14000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) changed 0.0% — and 2026, when it surged 3404.17%.
- Tracing CGON's Depreciation & Amortization (CF) over 4 years: stood at $4000.0 in 2023, then surged by 425.0% to $21000.0 in 2024, then soared by 3942.86% to $849000.0 in 2025, then retreated by 0.94% to $841000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $841000.0 (Q1 2026), $849000.0 (Q4 2025), and $416000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 850,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 850,000.00 |
| Jun 30, 2026 | 850,000.00 |
| Mar 31, 2026 | 841,000.00 |
| Mar 31, 2026 | 841,000.00 |
| Dec 31, 2025 | 849,000.00 |
| Dec 31, 2025 | 849,000.00 |
| Sep 30, 2025 | 416,000.00 |
| Sep 30, 2025 | 416,000.00 |
| Jun 30, 2025 | 156,000.00 |
| Jun 30, 2025 | 156,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Dec 31, 2023 | 4,000.00 |